FDA opens up an eth­i­cal can of worms with ac­cel­er­at­ed ap­proval for first drug for un­der­ly­ing ge­net­ic cause of dwarfism

The FDA on Fri­day signed off on an ac­cel­er­at­ed ap­proval for Bio­Marin’s Vox­zo­go (vosori­tide) in­jec­tion, the first treat­ment to tar­get the un­der­ly­ing ge­net­ics of dwarfism …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER